首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model
Authors:Narayan Sridhar  Carlson Eric M  Cheng Hongsheng  Condon Krista  Du Hong  Eckley Sean  Hu Yongbo  Jiang Yimin  Kumar Vipul  Lewis Bryan M  Saxton Philip  Schuck Edgar  Seletsky Boris M  Tendyke Karen  Zhang Huiming  Zheng Wanjun  Littlefield Bruce A  Towle Murray J  Yu Melvin J
Institution:Eisai Product Creation Systems, Eisai Inc., 4 Corporate Dr., Andover, MA 01810, USA
Abstract:Novel second generation analogs of eribulin mesylate, a tubulin agent recently approved for the treatment of breast cancer, are reported. Our recent efforts have focused on expanding the target indications for this class of compounds to other tumor types. Herein, we describe the design, synthesis and evaluation of eribulin analogs active against brain tumor cell lines in vitro and corresponding brain tumor models in mice. Attenuation of basicity of the amino group(s) in the C32 side-chain region led to compounds with lower susceptibility to P-gp mediated drug efflux, allowing these compounds to permeate through the blood-brain barrier. In preclinical in vivo studies, these compounds showed significantly higher levels in the brain and cerebrospinal fluid as compared to eribulin. In addition, analogs within this series showed antitumor activity in an orthotopic murine model of human glioblastoma.
Keywords:UFNVPOGXISZXJD-JBQZKEIOSA-N  JBFLNPIQVUSWKG-ZRAYEYSSSA-N
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号